I think your lying. And your probably voting for Trump. He's not qualified to work in a 7/11 and yet he's running for President. How divided, ignorant and embarrassing is this country. And lets not forget the media that fames the flames ONLY in their own economic interest. Woe is us. As if anything good will be accomplished in the next Senate and Congress, 4 more years of roadblocks. This is not what the founding fathers envisioned.
My guess is that many of the posters on this board that dabble in biotech are way under water and have gotten an expensive education on how difficult it is to make money.
Gern is Just another company that stole our money with false promises and major PR campaign's.
Yes, it's let the buy beware, but it's an unlevel playing field with much manipulation.
How many stocks have played us? Too many.
Really. your kidding right? And how many times has Gern been cheap?????????????????????
It's moronic comments like yours that cost idiots who listen to you money!
I'm voting for the only adult in the room. Someone who knows how government works. Someone who has a core philosophy. Someone who isn't only out for herself. Someone who releases tax returns. Someone who has Bill for advise. Someone who doesn't pander to the least educated most bigoted folks in America. Did I say the adult in the room?
You mean your not voting for the only adult in the room? take your blinders off. Trump doesn't have a clue how the country works, it's not a business. He must govern all the people. It's not a dictatorship.
Geron (GERN +6.4%) heads north on increased volume in response to its announcement of a license deal with Janssen Pharmaceuticals (JNJ +0.2%). The company has granted Janssen exclusive global rights to develop and commercialize products based on Geron's specialized oligonucleotide backbone chemistry in addition to RNA interference candidates for the treatment of all human disorders except blood and bone marrow cancers and exclusive of telomerase inhibitors.
Geron has also granted Janssen a non-exclusive global license to develop and commercialize oligonucleotides based on Geron's patents covering the synthesis of monomers (building blocks of oligonucleotides). Janssen Biotech has non-exclusive rights to the same intellectual property under their November 2014 imetelstat agreement.
Under the terms of the deal, Geron will receive an upfront payment of $5M, up to $75M in milestones and low-single-digit royalties on global net sales of each licensed product.
Where/what do Jkoka. Rokky44 and a host of others say now, buy more price is low?
Aside from Chen who admits to eating humble pie? You know who you are.
Wishing and hoping are not investment stragedy's (sp). No sure things. Don't believe everything you read. The odds are very, very, very long on biotech stocks. Many, many ,many things can/do go wrong.
SHAME ON THE PUMPERS! You will take responsibility for miscalls?????????????????